1-(piperidin-4-ylmethyl)-1H-benzimidazole | 852627-74-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-(piperidin-4-ylmethyl)-1H-benzimidazole
• 英文别名: 4-(1H-benzimidazol-1-ylmethyl)piperidine；1-Piperidin-4-ylmethyl-1H-benzoimidazole；1-(piperidin-4-ylmethyl)benzimidazole
• CAS: 852627-74-8
• 化学式: C₁₃H₁₇N₃
• mdl: MFCD01102045
• 分子量: 215.298
• InChiKey: QYSKIWPKKCCIEZ-UHFFFAOYSA-N

物化性质

• 沸点：
  380.4±34.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  29.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(piperidin-4-ylmethyl)-1H-benzimidazole 在 三乙酰氧基硼氢化钠 、 三氟乙酸 作用下， 以 二氯甲烷 、 苯甲醚 为溶剂， 生成 (R)-[(3S,4S)-3-(4-Benzoimidazol-1-ylmethyl-piperidin-1-ylmethyl)-4-phenyl-pyrrolidin-1-yl]-cyclohexyl-acetic acid
  参考文献：
  名称：

  Potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists: effects of fused heterocycles on antiviral activity and pharmacokinetic properties

  摘要：

  A series of 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists containing a variety of fused heterocycles at the 4-position of the piperidine side chain has been discovered, which are orally bioavailable with potent anti-HIV activity. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.02.030
• 作为产物：
  描述：

  1-苄基-4-哌啶甲醛 在 palladium on activated charcoal 盐酸 、 甲酸铵 、 三乙酰氧基硼氢化钠 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 1-(piperidin-4-ylmethyl)-1H-benzimidazole
  参考文献：
  名称：

  Potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists: effects of fused heterocycles on antiviral activity and pharmacokinetic properties

  摘要：

  A series of 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists containing a variety of fused heterocycles at the 4-position of the piperidine side chain has been discovered, which are orally bioavailable with potent anti-HIV activity. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.02.030

文献信息

• Cyclic amine compounds as CCR5 antagonists
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US06562978B1

  公开（公告）日：2003-05-13

  A compound of formula (I) (wherein R1 is a hydrogen atom, a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, R2 is a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, or R1 and R2 may combine to each other together with A to form a heterocyclic group which may be substituted; A is N or N+—R5.Y−(R5 is a hydrocarbon group; Y− is a counter anion); R3 is a cyclic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; n is 0 or 1; R4 is a hydrogen atom, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted, an alkoxy group which may be substituted, an aryloxy group which may be substituted, or an amino group which may be substituted, E is a divalent aliphatic hydrocarbon group which may be substituted by group(s) other than oxo; G1 is a bond, CO or SO2; G2 is CO, SO2, NHCO, CONH or OCO; J is methine or a nitrogen atom; and each of Q and R is a bond or a divalent C1-3 aliphatic hydrocarbon which may be substituted; provided that J is methine when G2 is OCO, that one of Q and R is not a bond when the other is a bond and that each of Q and R is not substituted by oxo group(s) when G1 is a bond) or a salt thereof has a potent CCR5 antagonistic activity and can be advantageously used for the treatment or prevention of infectious disease of various HIV in human (e.g. AIDS).

  式（I）的化合物（其中R1是氢原子，可能被取代的碳氢基团，可能被取代的非芳香杂环基团，R2是可能被取代的碳氢基团，可能被取代的非芳香杂环基团，或R1和R2可以彼此结合与A一起形成可能被取代的杂环基团；A是N或N+—R5.Y−（R5是碳氢基团；Y−是一个对离子）；R3是可能被取代的环烃基团或可能被取代的杂环基团；n为0或1；R4是氢原子，可能被取代的碳氢基团，可能被取代的杂环基团，可能被取代的烷氧基团，可能被取代的芳基氧基团，或可能被取代的氨基团；E是可能被除氧以外的基团取代的二价脂肪族碳氢基团；G1是键，CO或SO2；G2是CO，SO2，NHCO，CONH或OCO；J是亚甲基或氮原子；Q和R中的每一个是键或可能被取代的二价C1-3脂肪族碳氢基团；条件是当G2为OCO时J为亚甲基，当另一个为键时Q和R中的一个不是键，当G1为键时Q和R中的每一个都不被氧基取代）或其盐具有强大的CCR5拮抗活性，并可优势用于治疗或预防人类体内各种HIV引起的传染病（例如艾滋病）。
• Hexafluoroisopropyl Carbamates as Selective MAGL and Dual MAGL/FAAH Inhibitors: Biochemical and Physicochemical Properties
  作者：Maximilian Barth、Stefan Rudolph、Jan Kampschulze、Imke Meyer zu Vilsendorf、Walburga Hanekamp、Dennis Mulac、Klaus Langer、Matthias Lehr

  DOI：10.1002/cmdc.202100757

  日期：2022.5.4

  carbamates of heteroaryl-substituted alkylamines and alkylpiperidines were investigated for their inhibitory effects on fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL). Some of these substances were found to be selective inhibitors of MAGL, while others showed dual inhibition of both enzymes. Selected compounds were evaluated for their chemical and metabolic stability, water solubility

  研究了杂芳基取代的烷基胺和烷基哌啶的六氟异丙基氨基甲酸酯对脂肪酸酰胺水解酶 (FAAH) 和单酰基甘油脂肪酶 (MAGL) 的抑制作用。其中一些物质被发现是 MAGL 的选择性抑制剂，而另一些则显示出对两种酶的双重抑制作用。在 Caco-2 细胞渗透模型中评估了选定化合物的化学和代谢稳定性、水溶性和体外渗透性。
• [EN] CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS<br/>[FR] COMPOSES D'AMINE CYCLIQUE UTILISES COMME ANTAGONISTES DE CCR5
  申请人：TAKEDA CHEMICAL INDUSTRIES LTD

  公开号：WO2001025200A1

  公开（公告）日：2001-04-12

  A compound of formula (I) (wherein R1 is a hydrogen atom, a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, R2 is a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, or R?1 and R2¿ may combine to each other together with A to form a heterocyclic group which may be substituted; A is N or N?+-R5 •Y-(R5¿ is a hydrocarbon group; Y- is a counter anion); R3 is a cyclic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; n is 0 or 1; R4 is a hydrogen atom, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted, an alkoxy group which may be substituted, an aryloxy group which may be substituted, or an amino group which may be substituted, E is a divalent aliphatic hydrocarbon group which may be substituted by group(s) other than oxo; G1 is a bond, CO or SO¿2; G?2 is CO, SO¿2?, NHCO, CONH or OCO; J is methine or a nitrogen atom; and each of Q and R is a bond or a divalent C1-3 aliphatic hydrocarbon which may be substituted; provided that J is methine when G2 is OCO, that one of Q and R is not a bond when the other is a bond and that each of Q and R is not substituted by oxo group(s) when G?1¿ is a bond) or a salt thereof has a potent CCR5 antagonistic activity and can be advantageously used for the treatment or prevention of infectious disease of various HIV in human (e.g. AIDS).

  化合物式为（I）（其中R1是氢原子，可被取代的碳氢基团，可被取代的非芳香杂环基团，R2是可被取代的碳氢基团，可被取代的非芳香杂环基团，或R1和R2可以与A一起结合形成可被取代的杂环基团；A是N或N+ -R5 • Y-（R5是碳氢基团；Y-是反离子）；R3是可被取代的环烃基团或可被取代的杂环基团；n为0或1；R4是氢原子，可被取代的碳氢基团，可被取代的杂环基团，可被取代的烷氧基，可被取代的芳氧基，或可被取代的氨基，E是可被除氧基以外的基取代的二价脂肪烃基团；G1是键，CO或SO2；G2是CO，SO2，NHCO，CONH或OCO；J是甲基或氮原子；Q和R中的每一个都是一个键或一个可被取代的二价C1-3脂肪基团；前提是当G2是OCO时，J是甲基，当另一个是键时，其中一个不是键，当G1是键时，Q和R中的每一个都没有被氧基团取代）或其盐具有强效的CCR5拮抗活性，并可用于人类各种HIV感染疾病（例如艾滋病）的治疗或预防。
• 2-Aminopyrimidinone derivatives
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP0378254A2

  公开（公告）日：1990-07-18

  Novel 2-aminopyrimidinone derivatives of formula wherein -A¹=A²-A³=A⁴- is -CH=CH-CH=CH-, -N=CH-CH=CH-, -CH=N-CH=CH-, -­CH=CH-N=CH-, -CH=CH-CH=N-, -N=CH-N=CH-, -CH=N-CH=N-; B is NR⁸, CH₂, O, S, SO or SO₂; R⁸ is hydrogen, C₁₋₆alkyl, C₃₋₆cycloalkyl, C₁₋­₆alkylcarbonyl, C₁₋₆alkyloxycarbonyl or Ar²-C₁₋₆alkyl; R¹ is hydrogen, C₁₋₁₀alkyl, C₃₋₆cycloalkyl, Ar¹, mono- and di(Ar¹)-C₁₋₆alkyl, or a radical -Alk-G-R⁷; R², R³ are hydrogen or C₁₋₆alkyl; R⁴ is hydrogen, C₁₋₆alkyl optionally substituted with Ar², pyridinyl, furanyl, 5-methyl-2-furanyl or C₁₋₆alkyloxy; R⁵ is hydrogen, C₁₋₆alkyl, C₁₋₆alkylaminocarbonyl or Ar²-aminocarbonyl; R⁶ is hydrogen or C₁₋₆alkyl; or R⁵ and R⁶ taken together may form a bivalent radical of formula -CH₂-CH₂-, -CH₂-CH₂-CH₂-, -CH=CH-, -CH=N-, -N=CH-, -N=CH-CH₂-; n is 0, 1 or 2; the pharmaceutically acceptable acid addition salts and possible stereochemically isomeric forms thereof; pharmaceutical compositions containing such compounds as an active ingredient and methods of preparing said compounds and pharmaceutical compositions.

  式中的新型 2-氨基嘧啶酮衍生物 其中 -A¹=A²-A³=A⁴-是-CH=CH-CH=CH-、-N=CH-CH=CH-、-CH=N-CH=CH-、-CH=CH-N=CH-、-CH=CH-CH=N-、-N=CH-N=CH-、-CH=N-CH=N-； B 是 NR⁸、CH₂、O、S、SO 或 SO₂；R⁸ 是氢、C₁₋₆烷基、C₃₋₆环烷基、C₁₋₆烷基羰基、C₁₋₆烷氧基羰基或 Ar²-C₁₋₆烷基； R¹ 是氢、C₁₋₁₀、C₃₋₆环烷基、Ar¹、单-和二(Ar¹)-C₁₋₆烷基或自由基-Alk-G-R⁷； R²、R³是氢或 C₁₋₆烷基； R⁴ 是氢、任选被 Ar²、吡啶基、呋喃基、5-甲基-2-呋喃基或 C₁₋₆烷氧基取代的 C₁₋₆烷基； R⁵ 是氢、C₁₋₆烷基、C₁₋₆烷基氨基羰基或 Ar²- 氨基羰基； R⁶ 是氢或 C₁₋₆烷基；或 R⁵ 和 R⁶ 合在一起可形成式 -CH₂-CH₂-、-CH₂-CH₂-CH₂-、-CH=CH-、-CH=N-、-N=CH-、-N=CH-CH₂- 的二价基； n 为 0、1 或 2； 药学上可接受的酸加成盐及其可能的立体化学异构形式；含有此类化合物作为活性成分的药物组合物以及制备所述化合物和药物组合物的方法。
• Cyclic Amine Compounds as CCR5 Antagonists
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1886994A1

  公开（公告）日：2008-02-13

  A compound of the formula: (wherein R1 is a hydrogen atom, a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, R2 is a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, or R1 and R2 may combine to each other together with A to form a heterocyclic group which may be substituted; A is N or N+-R5 . Y- (R5 is a hydrocarbon group; Y- is a counter anion) ; R3 is a cyclic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; n is 0 or 1; R4 is a hydrogen atom, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted, an alkoxy group which may be substituted, an aryloxy group which may be substituted, or an amino group which may be substituted, E is a divalent aliphatic hydrocarbon group which may be substituted by group (s) other than oxo;G1 is a bond, CO or SO2 ; G2 is CO,S02, NHCO, CONH or OCO ; J is methine or a nitrogen atom; and each of Q and R is a bond or a divalent C1-3 aliphatic hydrocarbon which may be substituted; provided that J is methine when G2 is OCO, that one of Q and R is not a bond when the other is a bond and that each of Q and R is not substituted by oxo group (s) whenGo ils a bond) or a salt thereof has a potent CCR5 antagonistic activity and can be advantageously used for the treatment or prevention of infectious disease of various HIV in humans (e.g. AIDS).

  式中的化合物： (其中 R1 是氢原子、可被取代的烃基、可被取代的非芳香杂环基团，R2 是可被取代的烃基、可被取代的非芳香杂环基团，或 R1 和 R2 可与 A 相互结合形成可被取代的杂环基团；A 是 N 或 N+-R5 .Y-（R5 是烃基；Y- 是反阴离子）；R3 是可被取代的环烃基或可被取代的杂环基；n 是 0 或 1；R4 是氢原子、可被取代的烃基、可被取代的杂环基、可被取代的烷氧基、可被取代的芳氧基或可被取代的氨基；E 是可被除氧代以外的基团（s）取代的二价脂肪族烃基；G1 是键、CO 或 SO2；G2 是 CO、S02、NHCO、CONH 或 OCO；J 是甲烷或氮原子；Q 和 R 各自是键或可被取代的二价 C1-3 脂肪族烃；条件是：当 G2 为 OCO 时，J 为甲烷；当另一个为键时，Q 和 R 中的一个不是键；当 Go ils 为键时，Q 和 R 中的每一个没有被氧化基团（s）取代）或其盐具有强效的 CCR5 拮抗活性，可有利地用于治疗或预防人类各种 HIV 感染性疾病（如艾滋病）。例如艾滋病）。